Immunai Secures $215M for Immune System Map, Fuel More Acquisitions

Immunai wants to digitally map the immune system, and it’s amplified those efforts in recent months with two acquisitions and multiple funding rounds. The latest is a $215 million series B that will fund new partnerships, more acquisitions and a doubling of the team. 


The New York City-based startup, founded in 2018, hauled in the financing after already raising $60 million in February and a $20 million seed round last year. The fresh proceeds come after two acquisitions this year: single-cell genomics software firm Dropprint Genomics in March and Swiss bioinformatics company Nebion in July. 

Those acquisitions and Wednesday’s financing are geared toward elevating Immunai to the “largest single-cell immune database in the world,” said Noam Solomon, Ph.D., CEO and co-founder, in an interview with Fierce Biotech.


More To Explore